XNPT Related Analyst Ratings
-
Piper Jaffray Downgrades XenoPort (XNPT) to Neutral
-
Wells Fargo Raises Price Target on XenoPort (XNPT) on Positive '829 Data
-
Leerink Swann Starts XenoPort (XNPT) at Outperform; Pipeline Attractive
-
Wells Fargo Sees Continued Upside for XenoPort (XNPT); Profile Suggests '829 Lower-Risk Than Early Indications
-
Wells Fargo Starts XenoPort (XNPT) at Outperform; Multiple Catalysts for Near-Term Appreciation
-
Credit Suisse Starts XenoPort (XNPT) at Outperform
-
Deutsche Bank Cuts Price Target on XenoPort (XNPT), Horizant Continues to be Sluggish.
-
Wedbush Cuts Price Target on XenoPort (XNPT) by 30% Following Phase II Results of XP21279
-
Morgan Stanley Starts XenoPort (XNPT) at Equalweight
-
Canaccord Genuity on XenoPort ( XNPT): Feeling Restless?
-
Deutsche Bank Upgrades XenoPort (XNPT) to Buy; FDA Reverses Decision on Horizant
-
XenoPort (XNPT) Shares Higher Following Lazard Upgrade
-
Noble Financial Initiates Coverage on XenoPort (XNPT) with a Buy
-
Ladenberg Upgrades Xenoport (XNPT) To Buy
-
Wedbush Reiterates an 'Outperform' Rating on XenoPort (XNPT); Comments on FDA Advisory Panel Meeting for HORIZANT
-
Q4 Results Strong, Analysts Mixed; Traders Just Shrug and Sell Shares of XenoPort (XNPT)
-
Ladenburg Upgrades XenoPort (XNPT) to Neutral
-
Merriman Curhan Ford Downgrades DepoMed (DEPO) to Neutral
-
Xenoport (XNPT) Defended By Analyst After Yesterday's Free Fall
-
Benchmark Cuts XenoPort (XNPT) to Hold, Price Target Cut to $7
-
Parade of Analysts Downgrade XenoPort (XNPT) Following FDA Response Letter on Horizant
-
Rodman & Renshaw Downgrades XenoPort (XNPT) to Market Perform
-
Merriman Curhan Ford Downgrades Depomed, Inc. (DEPO) to Neutral
-
Ladenburg Thalmann & Lazard Capital Downgrade Xenoport (XNPT) to Sell
-
Morgan Stanley Downgrades Xenoport (XNPT) to Equalweight
-
Argus Downgrades Xenoport (XNPT) to Sell
-
Hapoalim Securities Downgrades XenoPort (XNPT) to Sell
-
Deutsche Bank Downgrades XenoPort (XNPT) to Hold; FDA Safety Concerns over Horizant
-
Cowen & Co Downgrades Xenoport (XNPT) to Neutral
-
Benchmark Upgrades Xenport (XNPT) to Buy; Believe Approval Likely for XP13512
-
Benchmark Initiates Coverage on XenoPort (XNPT) with a Hold
-
Piper Jaffray Maintains an Overweight on XenoPort (XNPT); Price Target Increased
-
Ladenburg Thalmann Upgrades Xenoport (XNPT) to Buy
-
Landenburg Thalman Downgrades XenoPort (XNPT) to Neutral
-
Lazard Downgrades XenoPort (XNPT) to Hold
-
Hapoalim Securities Initiates Coverage on Xenoport (XNPT) with a Market Outperform; Recent Dip Offers Compelling Entry Point
-
Credit Suisse Downgrades Xenoport (XNPT) to Neutral
-
Piper Jaffray Initiates Coverage on XenoPort (XNPT) with a Buy
-
Citi Downgrades XenoPort (XNPT) to Hold, Slashes Price Target
-
Lazard Upgrades XenoPort (XNPT) to Buy
-
Friedman Billings Upgrades XenoPort (XNPT) to Outperform
-
Goldman Sachs Starts Xenoport (XNPT) at Buy
-
Baird Initiates Coverage on Xenoport (XNPT) with an Outperform
-
Credit Suisse Starts Xenoport (XNPT) at Outperform
-
RBC Capital Initiates Coverage on XenoPort (XNPT) with an Outperform
-
Friedman Billings Downgrades XenoPort (XNPT) to Market Perform
-
Punk Ziegel upgrades Xenoport (XNPT) to Buy
-
Cowen Starts Xenoport (XNPT) at Outperform
-
Citigroup Upgrades XenoPort Inc (XNPT) to Buy
-
Piper Jaffray raised its price target on XenoPort (XNPT) to $59
Back to XNPT Stock Lookup
